Volume 20, Number 11—November 2014
Research
Drug-Resistant Candida glabrata Infection in Cancer Patients
Table 2
Factor | No. (%) cases |
Multivariate analysis |
||||
---|---|---|---|---|---|---|
Dose-dependent, n = 116 | Resistant, n = 30 | p value | Odds ratio (95% CI) | p value | ||
Hematologic malignancy | 27 (23.27) | 20 (66.66) | <0.001 | 3.63 (1.18–11.17) | 0.024 | |
Leukemia | 12 (10.34) | 10 (33.33) | <0.001 | |||
HSCT | 6 (5.17) | 10 (33.33) | <0.001 | |||
Monocytopenia, <100 cells/μL | 26 (22.41) | 13 (43.33) | 0.021 | |||
Any corticosteroids† | 60 (51.72) | 25 (83.33) | 0.002 | |||
Intensive care unit stay | 42 (36.21) | 17 (56.66) | 0.042 | |||
Mechanical ventilation | 17 (14.66) | 10 (33.33) | 0.019 | 3.96 (1.16–13.51) | 0.028 | |
Presence of a central line | 101 (87.06) | 30 (100) | 0.047 | |||
Azole exposure† | 24 (20.68) | 20 (66.66) | 0.001 | 5.09 (1.66–15.64) | 0.004 | |
Echinocandin exposure† | 17 (14.65) | 15 (50) | <0.001 | |||
Echinocandin resistance | 6 (5.17) | 9 (30) | <0.001 | 5.23 (1.31–20.78) | 0.019 |
*Blank cells indicate that the respective variables did not contribute significantly and were not retained in the final multivariate model (p>0.1). HSCT, hematopoietic stem cell transplantation.
†Within 1 month before the day of candidemia (day of blood collection for culture).
1Current affiliation: Harvard Medical School Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
Page created: October 15, 2014
Page updated: October 15, 2014
Page reviewed: October 15, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.